Amlodipine and calcineurin inhibitor‐induced nephrotoxicity following allogeneic hematopoietic stem cell transplant

Studies in the renal transplant population have suggested calcium‐channel blockers (CCBs) may protect against calcineurin inhibitor (CNI)‐induced nephrotoxicity. However, this has not been evaluated in the hematopoietic stem cell transplant (HSCT) population. This retrospective study reviews data from 350 consecutive patients who underwent allogeneic HSCT to determine whether amlodipine improved renal outcomes. Subject data included up to one year from CNI initiation. Patients in the amlodipine group (n = 130) received an average of 143 days treatment with amlodipine and experienced a smaller decrease in creatinine clearance (CrCl) through day 180. At day 30, change in CrCl was −17.4 mL/min in the amlodipine cohort and −33.8 mL/min in the control (P